Skip to main content

ASH Highlights

Meeting Highlights
ASH Highlights, Clinical Trials, Lymphoma
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma
Read More
Meeting Highlights
ASH Highlights, Graft-versus-Host-Disease
Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results
Read More
Meeting Highlights
ASH Highlights, Myelodysplastic Syndromes
Pevonedistat plus Azacitidine Improves Outcomes versus Azacitidine Monotherapy in High-Risk MDS
Read More
Meeting Highlights
ASH Highlights
A Phase 2 Study of Isatuximab for Patients with Previously Treated AL Amyloidosis
Read More
Meeting Highlights
ASH Highlights
VRD Consolidation Followed by Lenalidomide Maintenance versus Maintenance Alone in Transplant-Eligible Patients with NDMM
Read More
Meeting Highlights
ASH Highlights
A Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for RRMM
Read More
Meeting Highlights
ASH Highlights
Phase 2 GRIFFIN Study Update: Daratumumab + Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Eligible NDMM
Read More
Meeting Highlights
ASH Highlights
AMG 701, a Bispecific T-Cell Engager Molecule, in RRMM: A Phase 1 First-in-Human Study
Read More
Meeting Highlights
ASH Highlights
Selinexor in Combination with Pomalidomide and Dexamethasone for Treatment of Patients with RRMM
Read More
Meeting Highlights
ASH Highlights
Circularly Permuted TRAIL, a Novel TRAIL Agonist, with Thalidomide and Dexamethasone in Patients with RRMM
Read More
Page 2 of 7
Results 11 - 20 of 70